Teva Reports Second Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- UBS Reiterates Buy Rating on Snowflake Inc. (SNOW)
Teva Pharma (TEVA) Tops Q2 EPS by 3c, Offers Guidance
August 2, 2023 7:07 AM EDTTeva Pharma (NYSE: TEVA) reported Q2 EPS of $0.56, $0.03 better than the analyst estimate of $0.53. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.72 billion.
GUIDANCE:
Teva Pharma sees FY2023 EPS of $2.25-$2.55, versus the consensus... More
